Free Trial

Zenas BioPharma (ZBIO) Competitors

Zenas BioPharma logo
$16.71 +0.81 (+5.09%)
As of 08/13/2025 04:00 PM Eastern

ZBIO vs. FOLD, BCRX, CLDX, NVAX, INVA, DVAX, MNKD, OPK, GERN, and RIGL

Should you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.

Zenas BioPharma vs. Its Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Zenas BioPharma has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -6.67%. Zenas BioPharma's return on equity of 0.00% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amicus Therapeutics-6.67% -5.07% -1.23%
Zenas BioPharma N/A N/A N/A

Amicus Therapeutics presently has a consensus target price of $16.22, indicating a potential upside of 125.62%. Zenas BioPharma has a consensus target price of $36.67, indicating a potential upside of 119.43%. Given Amicus Therapeutics' higher possible upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Zenas BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Zenas BioPharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Amicus Therapeutics has higher revenue and earnings than Zenas BioPharma. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$528.29M4.20-$56.11M-$0.12-59.92
Zenas BioPharma$5M139.80-$156.99M-$3.55-4.71

In the previous week, Zenas BioPharma had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 8 mentions for Zenas BioPharma and 2 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.19 beat Zenas BioPharma's score of 0.29 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amicus Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zenas BioPharma
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Zenas BioPharma beats Amicus Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZBIO vs. The Competition

MetricZenas BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$665.16M$3.03B$5.54B$9.82B
Dividend YieldN/A2.27%4.62%4.12%
P/E Ratio-4.7120.6730.1526.03
Price / Sales139.80363.56461.08104.76
Price / CashN/A42.0537.7558.93
Price / Book2.237.638.476.06
Net Income-$156.99M-$54.65M$3.26B$265.11M
7 Day Performance12.91%5.41%4.18%3.38%
1 Month Performance30.34%7.14%4.63%2.28%
1 Year PerformanceN/A31.27%34.93%29.67%

Zenas BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZBIO
Zenas BioPharma
1.4955 of 5 stars
$16.71
+5.1%
$36.67
+119.4%
N/A$665.16M$5M-4.71N/ANews Coverage
Earnings Report
Upcoming Earnings
FOLD
Amicus Therapeutics
4.0857 of 5 stars
$6.98
+4.8%
$16.22
+132.4%
-38.7%$2.05B$528.29M-58.16480Positive News
BCRX
BioCryst Pharmaceuticals
4.157 of 5 stars
$8.35
+1.8%
$16.70
+100.0%
+8.1%$1.72B$450.71M-46.39530
CLDX
Celldex Therapeutics
1.1608 of 5 stars
$23.80
+18.9%
$51.75
+117.4%
-24.9%$1.33B$7.02M0.00150Positive News
Earnings Report
High Trading Volume
NVAX
Novavax
4.7433 of 5 stars
$8.48
+5.6%
$15.86
+87.0%
-27.2%$1.30B$682.16M3.721,990Analyst Revision
INVA
Innoviva
4.3241 of 5 stars
$20.09
+2.2%
$42.75
+112.8%
+11.1%$1.23B$358.71M64.81100News Coverage
Analyst Forecast
Analyst Revision
DVAX
Dynavax Technologies
4.2918 of 5 stars
$10.58
+1.0%
$24.33
+130.0%
-2.0%$1.23B$277.25M-23.00350Earnings Report
Analyst Revision
MNKD
MannKind
3.3346 of 5 stars
$3.66
+7.0%
$9.71
+165.4%
-26.4%$1.05B$285.50M33.28400Analyst Revision
OPK
OPKO Health
4.6269 of 5 stars
$1.32
+1.5%
$2.75
+108.3%
-11.2%$1.03B$713.10M0.002,997
GERN
Geron
3.2053 of 5 stars
$1.35
-0.7%
$4.19
+210.2%
-68.7%$867.70M$76.99M-10.38229Trending News
Analyst Revision
RIGL
Rigel Pharmaceuticals
1.3605 of 5 stars
$34.52
+3.2%
$38.20
+10.7%
+188.7%$600.18M$179.28M6.38160Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ZBIO) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners